Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acrivon Therapeutics, Inc.’s SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company focused on precision oncology. Its 8-K reports cover results of operations, financial condition, Regulation FD presentations, pipeline updates for ACR-368 and ACR-2316, and disclosures related to its internal CLIA-certified laboratory and companion diagnostic activities.
The company’s proxy materials describe annual meeting matters, board elections, auditor ratification, executive and director governance, and stockholder voting procedures. Filing records also identify the company’s common stock registration on Nasdaq and provide exhibits that support business updates, clinical program presentations, material agreements, and risk-related public-company reporting.
Acrivon Therapeutics reported second-quarter 2026 results and highlighted progress across its precision oncology pipeline built on its Generative Phosphoproteomics AP3 platform. The lead asset ACR-368 continues dosing in all-comer serous endometrial cancer arms of a registrational-intent Phase 2b trial, with a prespecified simultaneous interim analysis and data update from both arms planned for the second half of 2026 and a Phase 3 confirmatory trial targeted for the first half of 2027.
The company’s second program, ACR-2316, a WEE1/PKMYT1 inhibitor, has entered the randomized dose expansion stage of its Phase 1/2 study at 120 mg and 160 mg once-daily doses, with durable single-agent activity observed in several tumor types, including heavily pretreated lung cancers. Acrivon is also advancing an internally discovered CDK11 inhibitor program through IND-enabling studies, with an IND submission planned for the first half of 2027.
For the quarter ended June 30, 2026, Acrivon reported a net loss of $18.0 million, improved from $21.0 million a year earlier, as research and development and general and administrative expenses both declined. Cash, cash equivalents and investments totaled $90.0 million as of June 30, 2026, which the company expects to fund operations into the fourth quarter of 2027.
Acrivon Therapeutics, Inc. is a clinical-stage oncology company using its AP3 (Acrivon Predictive Precision Proteomics) platform to design and develop precision medicines. The lead asset ACR-368 (CHK1/2 inhibitor) is in a registrational-intent Phase 2b trial in endometrial cancer, guided by the protein-based OncoSignature assay and combinations such as ultra-low dose gemcitabine. Interim data cited include an overall response rate of 39% in OncoSignature-positive endometrial cancer Arm 1 and 52% in pooled serous endometrial cancer patients with ≤2 prior lines of therapy.
The second asset ACR-2316, a dual WEE1/PKMYT1 inhibitor, has advanced into randomized dose-expansion Phase 1/2 cohorts, while internally discovered CDK11 inhibitors remain in preclinical development. For the quarter ended June 30, 2026, Acrivon reported R&D expenses of $13.8 million and G&A expenses of $4.8 million, with a quarterly net loss of $18.0 million and a six‑month net loss of $37.0 million. Cash, cash equivalents and investments totaled $90.0 million as of June 30, 2026, after raising about $7.3 million via an at-the-market stock offering at $1.80 per share. The company states this liquidity is expected to fund operations into the fourth quarter of 2027. As of August 7, 2026, there were 42.9 million common shares outstanding.
Acrivon Therapeutics, Inc. Chief Financial Officer Adam D. Levy reported a sale of 1,142 shares of common stock on August 4, 2026 at $1.57 per share. The shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units, and he now directly holds 66,008 shares.
On 2026-07-21, Acrivon Therapeutics Chief Legal Officer Mary Miller had 573 shares of Common Stock sold at $1.76 per share. A note explains that the shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units. She continues to hold 82,194 shares directly after the transaction.
Acrivon Therapeutics, Inc. reported that entities affiliated with RA Capital are associated with a new stock option grant linked to director Dr. Derek DiRocco. The derivative award covers 20,275 shares of common stock at an exercise price of $1.52 per share, expiring on June 16, 2036. The option vests on the day before Acrivon’s next annual stockholder meeting, conditioned on Dr. DiRocco’s continued service. According to the disclosures, Dr. DiRocco holds the option for the benefit of RA Capital Healthcare Fund LP and RA Capital Nexus Fund II, and any net value from exercise will offset advisory fees owed to RA Capital Management, L.P., while the reporting persons disclaim beneficial ownership beyond their pecuniary interest.
Acrivon Therapeutics director Michael John Tomsicek received a stock option grant covering 20,275 shares of common stock. The option has an exercise price of $1.52 per share and expires on June 16, 2036. All 20,275 option shares are reported as held directly after this grant. The filing states that these options will vest on the date immediately preceding Acrivon’s next annual meeting of stockholders, provided he remains in continuous service through that vesting date. This is a compensation-related award and does not reflect an open-market purchase or sale of shares.
Acrivon Therapeutics, Inc. director Sharon Shacham received a grant of stock options representing 20,275 shares of common stock. The options have an exercise price of $1.52 per share and expire on June 16, 2036.
All 20,275 option shares remain held following the transaction. According to the grant terms, these options vest on the date immediately preceding Acrivon’s next annual meeting of stockholders, provided Shacham continues to serve through that vesting date.
Acrivon Therapeutics director Palani Santhosh received a stock option grant for 20,275 shares of common stock. The option has an exercise price of $1.52 per share and expires on June 16, 2036. All 20,275 option shares remain held following the grant. The option will vest on the date immediately preceding Acrivon’s next annual meeting of stockholders, conditioned on Santhosh’s continuous service through that vesting date.
Acrivon Therapeutics director Ivana Magovcevic-Liebisch received a new stock option grant. She was granted options to acquire 20,275 shares of Acrivon Therapeutics common stock at an exercise price of $1.52 per share.
The options are a compensation-related award, not an open-market purchase. They vest on the date immediately preceding the company’s next annual meeting of stockholders, as long as she remains in continuous service through that vesting date. Following this grant, she holds stock options for 20,275 underlying shares directly.
Acrivon Therapeutics director Derek DiRocco was granted a stock option covering 20,275 shares of common stock at an exercise price of $1.52 per share, expiring on June 16, 2036. The option vests immediately before Acrivon’s next annual stockholder meeting, subject to his continuous service.
The option is held for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P. Any net cash or stock from exercise must be turned over to RA Capital Management, L.P., and DiRocco disclaims beneficial ownership of the option and underlying shares.